$15 billion biotech stock loses more than 40% of its value after skin cancer drug study falls short
June 04, 2018 at 15:56 PM EDT
Shares of biotech Nektar Therapeutics lost nearly half their value Monday after the company gave a clinical trial update that fell well short of investor expectations.
